Article

Analytical Validation of NeXT Personal <sup>®</sup> , an Ultra-sensitive Personalized Circulating Tumor DNA Assay

2024-01-17

Abstract excerpt

<h4>ABSTRACT</h4> We describe the analytical validation of NeXT Personal ® , an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay for detecting residual disease, monitoring therapy response, and detecting recurrence in patients diagnosed with solid tumor cancers. NeXT Personal uses whole genome sequencing of tumor and matched normal samples combined with advanced analytics to accurately identif...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 03870efa-273c-5fd4-965f-2cc3c1c02e14
DOI: 10.1101/2024.01.17.23299863

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Analytical Validation of NeXT Personal <sup>®</sup> , an Ultra-sensitive Personalized Circulating Tumor DNA AssayDOI 10.1101/2024.01.17.23299863Read

Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.Semantic proximity Read

Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.Semantic proximity Read

Analytical validation and clinical utilization of K-4CARE<sup>TM</sup>: a comprehensive genomic profiling assay with personalized MRD detectionSemantic proximity Read

Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNASemantic proximity Read

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity Read

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageSemantic proximity Read

Analytical and Clinical Validation of an Amplicon-based Next Generation Sequencing Assay for Ultrasensitive Detection of Circulating Tumor DNASemantic proximity Read

Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNASemantic proximity Read

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNASemantic proximity Read

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.Semantic proximity Read

Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoringSemantic proximity Read

Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection.Semantic proximity Read